Biomarin awaits crucial approvals and flat growth in 2021
2021 could turn out to be an important year for Biomarin, which expects to get a growth hormone against dwarfism approved on the one hand, while battling health authorities in the US and the EU on the other, as the firm attempts to get approvals for its gene therapy against hemophilia.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Read this article for free
Register with your E-mail. No credit card required.